Not Yet RecruitingNot Applicable

Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax

Thailand300 participantsStarted 2026-05-01

Plain-language summary

This study is to conduct a clinical trial of tafenoquine combinations to compare the rates of therapeutic efficacy of dihydroartemisinin-piperaquine or artemether-lumefantrine with tafenoquine to chloroquine plus tafenoquine in preventing recurrence of Plasmodium vivax over a 6-month period in adult subjects with uncomplicated P. vivax infection living in Thailand.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants who meet all of the following criteria may participate in the study: * Thai or non-Thai, male or non-pregnant/non-lactating female, aged at least 18 years * Willingness to participate in the study and provides signed written informed consent form * Have P. vivax malaria mono-infection as determined by blood smear, with a parasitemia range of 100-400,000 parasites/microliter * Have normal (non-deficient or \>70% activity) G6PD phenotype as measured by quantitative spectrophotometry * Agree to not seek outside medical care prior to contacting the WRAIR-AFRIMS study team if a fever develops during study participation (approximately 180 days), unless emergency medical care is required Exclusion Criteria: * Participants meeting any of the following criteria will be excluded from this study: * Have an allergic reaction to any of the study drugs or components (AL,TQ, artemisinins, PPQ or CQ) * History of anti-malarial drug use within the past 14 days (28 days for mefloquine or PPQ) * On screening EKG, found to have a QTcF of greater than 450 milliseconds (ms) (470 ms for females) * History of sudden cardiac death in an immediate family member, or personal history of known symptomatic coronary artery disease or arrhythmias * Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, neurologic, or renal functional abnormality, as determined by history, physical examination, and laboratory evaluation; speci…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Estimate the rate of recurrence in all participants with uncomplicated P. vivax mono-infection in the 6 months following treatment with chloroquine, CQ, artemether-lumefantrine, AL, or dihydroartemisinin-piperaquine, DHA-PPQ, paired with tafenoquine, TQ

Timeframe: From enrollment to 6 months follow up

Trial details

NCT IDNCT07533136

SponsorWalter Reed Army Institute of Research (WRAIR)

Sponsor typeFED

Study typeINTERVENTIONAL

Primary completion2028-10-31

Contact for this trial

Dr. Krisada Jongsakul, MD

+66 2 696 2700 krisadaj.ca@afrims.org

View on ClinicalTrials.gov More Uncomplicated P. Vivax Mono-infection trials